{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2006"],"condition":["Rectum Cancer","Rectal Neoplasms","Colorectal cancer"],"disease":["Rectum Cancer","Rectal Neoplasms","Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2035218"],"location":["Netherlands"],"study_start_month":["9"],"keyword":["M-tor inhibitor","Sirolimus","Rapamycin"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer","description":"Investigating the safety and the activity of Rapamycin, administered before and during preoperative radiotherapy in patients with an operable colorectal carcinoma. The phase I dose escalation study will be performed in three steps (2, 4 and 6 mg). Patients entered in phase II will follow the same tolerable treatment regimen as patients in phase I study.","dates":{"creation":"2006-09-15"},"accession":"2035218","cross_references":{"ClinicalTrials___gov":["NCT00409994"]}}